We are excited to welcome Steve to Phathom during this important growth period for our Company,” said Michael Cola, Chairman of Phathom. “Steve is an accomplished biopharmaceutical leader with a ...

Stephen McAndrew, Ph.D., has been promoted to President and Chief Business Officer, as the company prepares to conduct a search for a permanent CEO ... Allowance from the United States Patent ...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word (s): Annual Report Newron presents 2024 financial results and provides 2025 outlook 01.04.2025 / 07:00 CET/CEST The issuer is solely responsible ...

United Therapeutics Corporation (Nasdaq ... at 12:05 Specright Announces Appointment of Mike Boese as CEO; Founder Matthew Wright Transitions to Executive Chairman Specright, the leader in ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 02, 2025--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Great Place ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Great Place to Work® and Fortune magazine recognized the company as one of the Fortune 100 Best ...

In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against other most profitable biotech stocks to buy right now. With improved market ...

Repare Therapeutics on Monday said its Chief Financial Officer, Steve Forte, has been named as the company's president and chief executive officer, effective April 11. He succeeds Lloyd Segal, who has ...

He joins Nuage from Pathios Therapeutics, an immuno-oncology company where he served as CEO and where he built the company from an initial seed investment to a clinical-stage organisation.

United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million.

Already reeling from years of market chaos, the announced departure of CBER chief Peter Marks sent a ripple across biopharma ...